A case of rhinoscleroma treated with ciprofloxacin by Badia, L & Lund, VJ
The Journal of Laryngology & Otology
March 2001, Vol. 115, pp. 220–222
A case of rhinoscleroma treated with cipro￿oxacin
Lydia Badia, F.R.C.S., Valerie J. Lund, M.S., F.R.C.S., F.R.C.S. (Ed)
Abstract
Respiratory scleroma (often termed ‘rhinoscleroma’) is a chronic in￿ammatory condition in which deforming
masses of tissue distend the nasal cavity. Klebsiella rhinoscleromatis is the causative agent of this infection and
the Mikulicz cell is speci￿c to the lesion being a large macrophage with clear cytoplasm containing the bacilli.
Antibiotic therapy has traditionally consisted of streptomycin and tetracycline long-term but this presents
problems with adverse side-effects and poor patient compliance.
We report on a young patient with nasal rhinoscleroma who achieved resolution after treatment with oral
cipro￿oxacin. As mentioned in a review of patients with rhinoscleroma at the Mayo clinic in 1993, the
￿uoroquinolones deserve further study as potentially highly effective agents for this condition. Cipro￿oxacin is
convenient for oral administration and has few adverse effects. It achieves good tissue penetration, is
concentrated in macrophages and may prove to be useful in the therapy of rhinoscleroma.
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Introduction
Rhinoscleroma was ￿rst described by Von Hebra in 1870.
Initially thought to be a neoplasm, it was established as an
in￿ammatory process in 1876 by Mikulicz and the
causative agent, Klebsiella rhinoscleromatis, isolated by
Von Frisch in 1882.
1 Although the disease may remain
con￿ned to the external nose and nasal cavity in some
patients, it often affects the entire respiratory tract and this
condition is therefore best termed ‘respiratory scleroma’.
Rhinoscleroma infection is worldwide but has a peculiar
geographical distribution being commoner in Central and
South America, some parts of Africa, the Middle East,
India, the Philippines and some other areas of the Paci￿c.
2
It seems to affect impoverished people, predominantly in
rural areas. It is a poorly communicable infection although
transmission after prolonged household contact with
infected family members has been reported.
3
It is rarely encountered in the UK and diagnosis is
frequently delayed because of the insidious onset, non-
speci￿c symptoms and equivocal ￿ndings on routine
histological examination. The causative organism is resis-
tant to most antibiotics and, being intracellular, is not
always exposed to suf￿cient concentrations of the drug.
We report on a case that achieved resolution during
treatment with oral cipro￿oxacin.
Case report
A 15-year-old Caucasian female noticed bilateral nasal
obstruction of a sudden onset at age ￿ve, followed by a
bilateral sensorineural hearing loss and later developed
insulin-dependent diabetes mellitus. She had undergone
adenoidectomy and sub-mucous diathermy of the inferior
turbinates in the past with temporary relief. Her older
sister had also suffered hearing loss and diabetes at
approximately the same age but had no nasal symptoms.
Examination revealed a diamond-shaped expansion of the
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Fig. 1
Coronal CT scan showing a diamond shaped expansion of the
cartilaginous nasal septum.
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mucosa in both nasal cavities, the rest of the physical
examination was normal. Nasal inspiratory peak ￿ow was
impossible due to the nasal obstruction, although oral
pulmonary peak ￿ow was normal for her age and height.
She was normotensive and skin prick testing to a range of
common allergens was negative. A computed tomography
(CT) scan (Figure 1) and magnetic resonance imaging
(MRI) con￿rmed expansion of the cartilagenous septum
with no signi￿cant sinus disease or any other pathology.
There was no evidence of bony erosion or destruction. She
underwent limited septal surgery and biopsies of the
septum and ￿oor of left nasal cavity showed disease
characteristic of rhinoscleroma (Figure 2), with a marked
mononuclear and plasma cell in￿ltrate and organisms seen
within foamy macrophages (Mikulicz’s cells).
Following the microbiologist’s advice she was started on
a course of cipro￿oxacin, 500.mg orally twice a day for
eight weeks. After one month of therapy, her symptoms
had resolved but the course of cipro￿oxacin was continued
for another four weeks. Examination showed a normal
nasal mucosa and nasal inspiratory peak ￿ow improved to
120 litres per minute. At 12 months after discontinuation of
therapy she remains asymptomatic and rhinoscleroma has
clinically cleared, biopsies at this stage were negative
although she remains under follow-up.
Discussion
Scleroma is a term used to describe an infectious disease
caused by a Gram negative diplobacillus. The term was
adopted in 1932 by the International Otolaryngology
Clinical Congress to emphasize that the disease process
can affect any area of the upper or lower respiratory tract,
not just the nasal vault and sinuses.
4 Nevertheless the less
accurate term ‘rhinoscleroma’ may endure because the
bacterium causing the infection is Klebsiella rhinoscler-
omatis. The presentation of scleroma varies, but the most
common symptom complex relates to nasal symptoms,
including nasal obstruction, purulent or foetid nasal
discharge and submucosal masses.
5 The clinical progres-
sion of scleroma is generally divided into three or four
phases of involvement that are thought to occur in
sequence if the infection remains incompletely treated.
Stage one is the exudative or catarrhal phase, character-
ized by profuse purulent in￿ammation. This is followed by
the atrophic phase, in which dry crusting of the mucous
membrane occurs and leads to friable, easily bleeding
tissue. Stage three is the granulomatous stage, in which
nodules and masses often proliferate and obstruct the
affected portion of the respiratory tract. Finally in the
cicatrical stage, scarring forms in the infected area.
4
With the availability of computed tomographic scanning
and nasal endoscopes, scleroma has been found to infect
the interior of the maxillary sinus as well as the ethmoid
sinuses more often than was typically reported before the
advent of this technology. Nasopharyngeal involvement
can occur and lead to eustachian tube dysfunction or to
ulceration of the soft palate with eventual scarring or
nasopharyngeal stenosis.
7 Scleroma occasionally involves
the subglottis, trachea or distal respiratory tract but in most
cases, the airway involvement occurs after nasal involve-
ment has been present, although isolated subglottic
involvement has also been reported.
8 The distribution of
scleroma involvement was reported by Gamea in 1990.
9 In
this study of 80 patients, 100 per cent had nasal vault
improvement involvement or rhinoscleroma, 22.5 per cent
had involvement of the maxillary sinus, 27.5 per cent had
involvement of the eustachian tube, 26 per cent had
laryngoscleroma, 20 per cent had tracheoscleroma, and 7.5
per cent had bronchoscleroma. In this report the role of
endoscopy is emphasized, including sinus endoscopy and
bronchoscopy, in evaluating scleroma.
The diagnosis of scleroma will be obtained by culture
material and biopsy of the affected area.
10 Klebsiella
rhinoscleromatis can usually be grown in the laboratory on
blood agar or MacConkey agar. Culture results are
important because they con￿rm the diagnosis and guide
future antibiotic choices through sensitivities obtained in
vitro. The organisms can be visualized on routine HE
staining and their presence (Gram negative diplobacilli)
con￿rmed on Gram staining. Microscopic ￿ndings vary
depending on the stage of involvement, but a classic
manifestation is the presence of Mikulicz cells (Figue 2)
which are large macrophages with clear cytoplasm contain-
ing the bacilli. The organism is encapsulated within a
mucopolysaccaride coat that confers antibiotic resistance.
Special silver stains, such as Warthin-Starry and Giemsa,
are often required to reveal the classic histological picture.
Immunohistochemical techniques are now also available,
with the capsular antigen O2K3 being the basis for
immunoperoxidase testing.
4
In the pre-antibiotic era, the mainstay of therapy for
scleroma was surgery, particularly in the late ￿brotic stage
with airway problems due to obstruction or dis￿gurement.
Many antibiotic have been tried against scleroma. Clinical
response can be obtained with different drugs but relapses
result from incomplete treatment.
11 Systemic streptomycin
was the ￿rst drug to be used successfully and for years it
was the drug of choice but it has severe side-effects,
especially in the vestibular system and it has now acquired
resistance. When tetracycline was introduced it had the
facility of oral administration, but it required prolonged
therapy in terms of months or years with poor patient
compliance. Tetracycline is to be avoided in the paediatric
age group and during pregnancy because of teeth
staining.
12 Rifampicin has also been shown to have good
results, but patients recieving rifapicin must be closely
monitored for sign of toxicity. To avoid the systemic effects
of rifampicin, topical rifampicin has been used with good
results.
13 Trimethoprim-sulfamethoxazole has been found
to be effective, and its low cost is especially important in
third world nations.
5
Fig. 2
Microscopic appearance of the nasal mucosa which shows
fibrosis and a mixed inflammatory cell infiltrate. The inflam-
mation is chronic, featuring plasma cells, lymphocytes and
macrophages. The Mikulicz cells are large macrophages with
clear cytoplasm containing rodlike structures (H.&.E; 3 340).
clinical records 221Most recently, quinolones have been reported as
adequate treatment.
4 Cipro￿oxacin, a ￿uoroquinolone, is
an antibiotic with excellent tissue penetration and a broad
antibacteria spectrum of action. Adverse effects are
comparatively few and include gastrointestinal symptoms
in three to six per cent of patients. Its use is not
recommended in patients under 12 years of age because
of the risk of arthropathy. Cipro￿oxacin has the advantage
of twice-daily administration, that may improve compli-
ance for long courses of therapy. Another theoretical
advantage is that the quinolones are concentrated within
macrophages.
14 Cipro￿oxacin, 250–500.mg administred
twice daily for four weeks, was shown to have excellent
clinical ef￿cacy in an area of Mexico where scleroma is
endemic.
15 It was also cheaper in the long run than drugs
with a lower initial cost that required longer periods of
treatment. There have been other case reports of rhino-
scleroma cured with cipro￿oxacin
16–18 but the appropriate
duration of antibiotic therapy has not been established.
Most authors suggest continuing treatment until repeated
tissue culture and histological exmination are negative for
the bacillus. Long-term follow-up is required to monitor
for re-activation of disease after treatment.
In conclusion, there is growing evidence that cipro-
￿oxacin is an appropriate antimicrobial agent and possibly
shortens the duration of therapy. Further investigation of
the use of cipro￿oxacin for treatment of rhinoscleroma,
including comparative trials with other therapies, would be
of considerable interest.
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